Business Description
Surmodics Inc
NAICS : 325413
SIC : 3845
ISIN : US8688731004
Description
Surmodics Inc is a provider of surface modification and in vitro diagnostic technologies to the healthcare industry. The company's mission is to improve the treatment and detection of disease by using its technology to provide solutions to difficult medical devices and diagnostic challenges. It has two reportable segments: Medical device unit; Manufacture of performance coatings, including surface modification coating technologies and the Vitro diagnostics unit; Manufacture of chemical and biological components used in in vitro diagnostic immunoassay and molecular tests within the diagnostic and biomedical research markets. Surmodics derives majority of its revenue from the Medical Device segment.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.04 | |||||
| Equity-to-Asset | 0.68 | |||||
| Debt-to-Equity | 0.28 | |||||
| Debt-to-EBITDA | 1.54 | |||||
| Interest Coverage | 3.51 | |||||
| Piotroski F-Score | 8/9 | |||||
| Altman Z-Score | 6 | |||||
| Beneish M-Score | -2.64 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 11.2 | |||||
| 3-Year EBITDA Growth Rate | 33.9 | |||||
| 3-Year EPS without NRI Growth Rate | 24 | |||||
| 3-Year FCF Growth Rate | -10.3 | |||||
| 3-Year Book Growth Rate | -4 | |||||
| Future 3-5Y Total Revenue Growth Rate | 5.27 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 41.5 | |||||
| 9-Day RSI | 40.34 | |||||
| 14-Day RSI | 39.62 | |||||
| 6-1 Month Momentum % | -6.57 | |||||
| 12-1 Month Momentum % | 20.75 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.84 | |||||
| Quick Ratio | 3.97 | |||||
| Cash Ratio | 2.13 | |||||
| Days Inventory | 72.34 | |||||
| Days Sales Outstanding | 30.48 | |||||
| Days Payable | 14.27 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.2 | |||||
| Shareholder Yield % | -3.92 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 48.61 | |||||
| Operating Margin % | 9.05 | |||||
| Net Margin % | 4 | |||||
| FCF Margin % | 7.1 | |||||
| ROE % | 4.89 | |||||
| ROA % | 3.1 | |||||
| ROIC % | 5.25 | |||||
| ROC (Joel Greenblatt) % | 34.53 | |||||
| ROCE % | 8.52 | |||||
| Years of Profitability over Past 10-Year | 7 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 69.68 | |||||
| PE Ratio without NRI | 56.22 | |||||
| Shiller PE Ratio | 140.2 | |||||
| Price-to-Owner-Earnings | 240.73 | |||||
| PS Ratio | 2.7 | |||||
| PB Ratio | 3.09 | |||||
| Price-to-Tangible-Book | 7.37 | |||||
| Price-to-Free-Cash-Flow | 37.83 | |||||
| Price-to-Operating-Cash-Flow | 29.72 | |||||
| EV-to-EBIT | 26.85 | |||||
| EV-to-EBITDA | 16.23 | |||||
| EV-to-Revenue | 2.59 | |||||
| EV-to-Forward-Revenue | 3.12 | |||||
| EV-to-FCF | 38.09 | |||||
| Price-to-Projected-FCF | 2.97 | |||||
| Price-to-Median-PS-Value | 0.5 | |||||
| Price-to-Graham-Number | 4.31 | |||||
| Price-to-Net-Current-Asset-Value | 17.45 | |||||
| Earnings Yield (Greenblatt) % | 3.73 | |||||
| FCF Yield % | 2.75 | |||||
| Forward Rate of Return (Yacktman) % | -14.78 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Surmodics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 128.069 | ||
| EPS (TTM) (€) | 0.351 | ||
| Beta | 0.8 | ||
| Volatility % | 79.69 | ||
| 14-Day RSI | 39.62 | ||
| 14-Day ATR (€) | 0.344668 | ||
| 20-Day SMA (€) | 25.04 | ||
| 12-1 Month Momentum % | 20.75 | ||
| 52-Week Range (€) | 16.2 - 35.2 | ||
| Shares Outstanding (Mil) | 14.24 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Surmodics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Surmodics Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Surmodics Inc Frequently Asked Questions
What is Surmodics Inc(FRA:SU6)'s stock price today?
The current price of FRA:SU6 is €24.60. The 52 week high of FRA:SU6 is €35.20 and 52 week low is €16.20.
When is next earnings date of Surmodics Inc(FRA:SU6)?
The next earnings date of Surmodics Inc(FRA:SU6) is 2024-04-26 Est..
Does Surmodics Inc(FRA:SU6) pay dividends? If so, how much?
Surmodics Inc(FRA:SU6) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers